Peptides: BPC-157, TB-500 and What the Evidence Actually Shows

Peptides arrived in gyms the way SARMs did a decade ago. Someone in the changing room is injecting something for a shoulder that has not healed. A clinic near you offers a recovery protocol. A podcast host describes a compound that repairs tendons, and by the end of the week it is on order.

The pitch is compelling because it sounds precise. These are not steroids. They are short chains of amino acids, the same building blocks your body already uses, targeted at specific processes rather than blanketing your system with hormones.

That framing is accurate. What it leaves out is that for the most popular ones, almost nobody has tested whether they work in humans.

What a peptide actually is

A peptide is a short chain of amino acids, shorter than a protein. Your body makes thousands of them, and several are genuine, approved medicines: insulin is a peptide, and so is semaglutide.

So "peptides" is not a category that tells you anything about safety or evidence, any more than "tablets" would. What matters is which specific compound, and what has been done to test it.

The ones sold for recovery and performance divide into two groups, and the distinction matters.

Tissue repair compounds: BPC-157, TB-500. Marketed for tendons, gut healing, injury recovery.

Growth hormone secretagogues: CJC-1295, ipamorelin, sermorelin. These prompt your pituitary to release more of your own growth hormone rather than supplying it directly, which is a meaningfully different proposition from injecting growth hormone. Growth hormone and insulin in bodybuilding covers the older practice.

BPC-157, and the gap the marketing skips

BPC-157 is the most talked-about of them, so it is worth being precise.

It is a synthetic fifteen-amino-acid fragment of a sequence found in gastric juice. The preclinical literature is genuinely substantial: more than thirty years of animal research and close to two hundred published studies, showing effects on tendon, muscle, gut and nerve healing in rodents.

Now the human evidence, in full.

• A case series of 16 patients with knee pain
• An open-label pilot in 12 women with interstitial cystitis, no control group
• A report involving 2 subjects given intravenous infusion

That is the published human record. No randomised controlled trials. No published pharmacokinetics. Nobody has established what dose reaches your bloodstream, how long it stays, or what it does over years.

The gap between two hundred animal studies and three uncontrolled human reports is the entire subject, and it is the part the clinic website will not mention.

Animal results failing to replicate in humans is the normal outcome in drug development, not the exception. Most compounds that work in rodents do not work in people.

The regulatory situation, which is genuinely confusing right now

This changed twice in three years, and the current position is easy to misread.

September 2023. The FDA placed roughly nineteen peptides into Category 2, meaning compounding pharmacies could no longer legally prepare them. The stated concerns were immunogenicity, manufacturing impurities, and insufficient safety data. BPC-157, TB-500, CJC-1295, ipamorelin and others disappeared from legitimate supply overnight.

February 2026. The US Health Secretary announced on a podcast that around fourteen of the nineteen would move back toward Category 1.

April 2026. BPC-157, TB-500 and CJC-1295 were removed from Category 2 after their nominations were withdrawn. They were not moved to Category 1.

July 2026. The FDA's compounding advisory committee reviewed BPC-157, TB-500, KPV and MOTS-C for eligibility. Further compounds are scheduled through to early 2027.

Here is the sentence that matters, because online sellers are already blurring it: coming off a restricted list is not approval. None of these compounds has completed clinical trials. None is an approved medicine. Removal from Category 2 without addition to Category 1 leaves them in a zone where they are neither explicitly banned nor authorised.

The announcement created demand before any quality oversight existed, which is the worst possible sequence.

Where they are actually coming from

Because legitimate pharmacy access was restricted for two years, most peptides bought in the last three years came from somewhere else.

The usual route is an overseas vendor selling "research use only" powder. That phrase is a legal device, not a description. It exists so the seller is not marketing a drug for human use, while both parties understand exactly what it is for.

Buyers reassure themselves with certificates of analysis showing 98 or 99 per cent purity. Those certificates are frequently produced by laboratories connected to the vendors themselves, and even a genuine purity figure tells you nothing about what the remaining one or two per cent contains, whether the vial is sterile, or whether the contents match the label.

Health Canada has warned against buying unauthorised peptides online, naming BPC-157, CJC-1295, ipamorelin and TB-500 specifically, and has seized products. In the US, the Department of Justice prosecuted a compounding company over unapproved peptides including BPC-157, resulting in a forfeiture of $1.79 million.

This is the same pattern as SARMs a decade earlier, and it ended the same way. SARMs: the science and the risks covers that history, including how often the vial contained something other than the label claimed.

What is actually known about safety

The honest answer is: not enough to say, and that is different from saying they are dangerous.

BPC-157 has a favourable safety profile in animals, with few adverse effects reported. But long-term human safety, pharmacokinetics and any cancer risk signal are simply undefined. Absence of evidence is not evidence of safety, particularly for a compound that promotes tissue growth and blood vessel formation.

The FDA's stated concerns were immune reactions and impurities. A serious adverse event involving ipamorelin occurred with intravenous infusion, well outside typical use.

One practical point for anyone who competes: BPC-157 falls under the World Anti-Doping Agency's S0 category covering unapproved substances. A sanction does not require the compound to be individually listed.

The compounds with more behind them

Not everything in this space is equally thin, and it would be lazy to lump them together.

CJC-1295 and ipamorelin have meaningful human data showing restoration of growth hormone pulse patterns, with downstream effects on body composition and sleep. They work upstream, prompting your own pituitary, so your feedback systems stay intact and supraphysiological levels are not produced. That is a genuinely better safety architecture than injecting growth hormone.

Sermorelin sits in a different regulatory category with its own history and remains available.

Thymosin alpha-1 is an approved pharmaceutical in more than thirty countries for hepatitis and as an oncology adjunct, though not in the US.

None of this makes them appropriate for a healthy man who wants to recover faster from training. It means the evidence gradient within this category is steep, and "peptides" as a single word hides it.

How to think about this

If you are considering peptides, four questions are worth answering honestly.

What am I actually treating? A tendon injury that has not healed in nine months is a different situation from wanting faster recovery between sessions. The first deserves a proper diagnosis first, because a peptide will not fix a tear that needs surgery.

Have I done the boring things? Sleep, protein, progressive loading and time heal most soft tissue injuries. A compound with no human trials is a strange first choice when the interventions with actual evidence have not been tried.

Where is this coming from? A physician-supervised, pharmacy-sourced product is a different risk profile from a powder posted from overseas. If your answer involves a Telegram group, you are running an experiment on yourself with unknown material.

What would change my mind? If the answer is "a randomised trial," note that none exists for the compound you are considering. If the answer is "testimonials," that is the same evidence standard that sold every supplement on the list of things men waste money on.

What I would tell a friend

The regulatory noise of 2026 has been widely reported as peptides becoming legal again. That is not what happened, and the distinction is not pedantic.

What happened is that a restriction was lifted while the evidence base stayed exactly where it was. BPC-157 has the same three small human reports it had in 2023. The trials that would settle the question have not been run.

That does not mean these compounds are useless. BPC-157 may well turn out to help a specific condition, and the preclinical work is real. The correct response is not to dismiss it, but to want the blinded, placebo-controlled human trials that would actually answer the question.

Until those exist, anyone injecting these is a participant in an uncontrolled experiment with no data collection, no follow-up, and no way to know whether the vial contains what the label says.

Some men are comfortable being that participant. Doing it knowingly is a very different thing from doing it because a podcast made it sound settled.

Common questions

Are peptides legal in 2026?

The situation is unresolved. BPC-157, TB-500 and CJC-1295 were removed from the FDA's restricted Category 2 in April 2026 but not added to the permitted list, leaving them neither banned nor authorised. None is an approved medicine.

Does BPC-157 work?

In animals, consistently. In humans, unknown. The published human evidence is a 16-patient case series, a 12-patient uncontrolled pilot, and a 2-subject report. There are no randomised controlled trials and no published pharmacokinetic data.

Is BPC-157 safe?

Animal data show few adverse effects, but long-term human safety, dosing and any cancer risk are undefined. The FDA cited immunogenicity and impurity concerns. Absence of evidence is not evidence of safety.

Are peptides the same as steroids?

No. Anabolic steroids are synthetic androgens acting on hormone receptors throughout the body. Peptides are amino acid chains with more specific targets. That makes them mechanistically different, not automatically safer or better evidenced.

Will peptides show on a drugs test?

BPC-157 falls under WADA's S0 category for unapproved substances, so it is prohibited in tested sport without needing to be individually listed.

What about CJC-1295 and ipamorelin?

Better evidenced than BPC-157. They prompt your own pituitary rather than supplying growth hormone, so feedback systems stay intact. Still not approved, and still not a reasonable first step for a healthy man.

Sources: Jozwiak M et al., Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review, Pharmaceuticals 2025;18:185 · Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, PubMed 2026 · US Food and Drug Administration, Bulk drug substances nominated for use in compounding under section 503A, updated May 2026 · Health Canada advisory on unauthorised peptide products sold online, 2026 · US Anti-Doping Agency, BPC-157: experimental peptide creates risk for athletes · Educational only, not medical advice. These compounds are not approved medicines and should not be self-administered.

Keep reading: SARMs: the science and the risks · Growth hormone and insulin in bodybuilding · Anabolic steroid side effects · Supplements that waste your money · Blood work for lifters · TRT side effects